GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (NAS:XNCR) » Definitions » Shiller PE Ratio
中文

Xencor (Xencor) Shiller PE Ratio

: (As of Today)
View and export this data going back to 2013. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


Xencor Shiller PE Ratio Historical Data

The historical data trend for Xencor's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xencor Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xencor Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Xencor's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xencor Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Xencor's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xencor's Shiller PE Ratio falls into.



Xencor Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Xencor's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Xencor's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.31/129.4194*129.4194
=-0.310

Current CPI (Dec. 2023) = 129.4194.

Xencor Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.120 99.695 -0.156
201406 -0.160 100.560 -0.206
201409 -0.200 100.428 -0.258
201412 -0.043 99.070 -0.056
201503 -0.190 99.621 -0.247
201506 -0.220 100.684 -0.283
201509 -0.250 100.392 -0.322
201512 0.190 99.792 0.246
201603 -0.160 100.470 -0.206
201606 1.130 101.688 1.438
201609 -0.200 101.861 -0.254
201612 -0.210 101.863 -0.267
201703 -0.330 102.862 -0.415
201706 -0.170 103.349 -0.213
201709 -0.480 104.136 -0.597
201712 -0.250 104.011 -0.311
201803 -0.620 105.290 -0.762
201806 -0.460 106.317 -0.560
201809 0.050 106.507 0.061
201812 -0.320 105.998 -0.391
201903 1.380 107.251 1.665
201906 -0.280 108.070 -0.335
201909 -0.180 108.329 -0.215
201912 -0.470 108.420 -0.561
202003 -0.140 108.902 -0.166
202006 -0.610 108.767 -0.726
202009 -0.220 109.815 -0.259
202012 -0.240 109.897 -0.283
202103 -0.040 111.754 -0.046
202106 0.870 114.631 0.982
202109 -0.690 115.734 -0.772
202112 1.210 117.630 1.331
202203 0.390 121.301 0.416
202206 -0.570 125.017 -0.590
202209 -0.550 125.227 -0.568
202212 -0.200 125.222 -0.207
202303 -1.020 127.348 -1.037
202306 -0.370 128.729 -0.372
202309 -0.400 129.860 -0.399
202312 -0.310 129.419 -0.310

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xencor  (NAS:XNCR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Xencor Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Xencor's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xencor (Xencor) Business Description

Traded in Other Exchanges
Address
111 West Lemon Avenue, Monrovia, CA, USA, 91016
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Executives
Bassil I Dahiyat director, officer: PRESIDENT & CEO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Barbara Klencke director C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Allen Yang officer: SR. VICE PRESIDENT & CMO C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Celia Eckert officer: VP, GENERAL COUNSEL C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John R Desjarlais officer: SR. VICE PRESIDENT & CSO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John J Kuch officer: SR. VICE PRESIDENT & CFO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Nancy Valente director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Richard J Ranieri director 3005 FIRST AVE, SEATTLE WA 98121
Ellen Feigal director C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Yujiro S Hata director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Alan Bruce Montgomery director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Kevin Charles Gorman director 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Kurt A Gustafson director 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Stafford John S Iii 10 percent owner 230 SOUTH LASALLE STREET 400, CHICAGO IL 60604